-
Uncategorized2 months ago
Merck, Eisai’s Keytruda triplet fails to improve survival in kidney cancer
A triplet regimen comprising Merck’s Welireg and PD-1 blockbuster Keytruda and Eisai’s Lenvima flopped in a Phase 3 renal cell carcinoma trial.
-
Uncategorized2 months ago
AACR 2026: Moderna, Revolution, Zymeworks and BeOne showcase new data
Moderna, Revolution Medicines and Zymeworks record wins in melanoma, lung and breast cancers, while BeOne swings and misses at head and neck cancer.
-
Uncategorized2 months ago
Where Utah’s experiment with AI doctors is headed next
Companies looking to push the limits of artificial intelligence in healthcare are heading to Utah, where the state is giving them flexibility to use the technology...
-
Uncategorized2 months ago
Gilead, Arcus tumble again in TIGIT, triggering 2 trial culls
Gilead, Arcus tumble again in TIGIT, triggering 2 trial culls
-
Uncategorized2 months agoSTAT+: Kennedy hints at coming breakthrough device announcement
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your...
-
Uncategorized2 months ago
AACR 2026: A Video Update from San Diego
The American Association for Cancer Research (AACR) meeting is off and running in San Diego. Julianna LeMieux, PhD, Deputy Editor in Chief at GEN, and Damian...
-
Uncategorized2 months agoSTAT+: BioAge says experimental pill aimed at reducing heart risks significantly reduced inflammation
BioAge Labs said Tuesday that its investigational pill for cardiovascular risk prevention significantly reduced inflammation in an early study, as more drug companies target inflammation as...
-
Uncategorized2 months ago
Soleno sold at a discount to Neurocrine due to dwindling European prospects
Soleno sold at a discount to Neurocrine due to dwindling European prospects
-
Uncategorized2 months ago
Serif, Flagship’s latest biotech, aims to make a new kind of genetic medicine
The startup is developing “modified DNA” therapies it claims can combine the strengths of multiple approaches, from messenger RNA to gene therapy. Read More
-
Uncategorized2 months agoOpinion: What happens when a chief executive loses executive functions?
Circa 1970, the renowned Russian neuropsychologist Alexander Luria together with Karl Pribram from Stanford University and other neuroscientists of that era introduced the term “executive functions” into the scientific lexicon to denote...
